Technology dealmaking has continued apace in 2020 as M&A investors take advantage of the sector's resilience to transact

The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis

The year started strongly for many nations in Latin America, but coronavirus has heavily impacted the M&A market.

COVID-19 is hammering leisure sector M&A—but not so much that opportunities have vanished

COVID-19 travel restrictions have put the aviation industry on the backfoot. M&A will not be an immediate priority, but consolidation and distressed deals will come in time

COVID-19 has put dealmaking in the already disrupted retail industry under further strain. Some retailers, however, have proven resilient and those that survive will see opportunity to vertically integrate supply chains and invest in technology capabilities

Oil & gas dealmaking has plummeted following a period of prolonged low oil prices and a steep fall in demand due to COVID-19. However, large players with strong balance sheets could still see opportunities to invest

We highlight the responses companies are taking in light of the current environment and the arguments some buyers are making to terminate transactions

A selection of key legal and practical considerations amidst the COVID-19 pandemic

In 2019, we advised on 310 announced M&A deals worldwide with an aggregate value exceeding US$382 billion

2019 proved challenging for oil & gas M&A in the face of a volatile crude price and weaker economic growth

2019 was one of the best years on record—and there’s reason to believe the trend will continue in 2020